Cullinan Therapeutics, Inc. (CGEM)
15.51
+0.98
(+6.74%)
USD |
NASDAQ |
Oct 02, 16:00
15.55
+0.04
(+0.26%)
Pre-Market: 08:58
Cullinan Therapeutics Net Income (Quarterly) : -53.70M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -53.70M |
| March 31, 2026 | -49.66M |
| December 31, 2025 | -50.71M |
| September 30, 2025 | -50.61M |
| June 30, 2025 | -70.06M |
| March 31, 2025 | -48.50M |
| December 31, 2024 | -47.65M |
| September 30, 2024 | -40.56M |
| June 30, 2024 | -42.03M |
| March 31, 2024 | -37.34M |
| December 31, 2023 | -25.56M |
| September 30, 2023 | -39.18M |
| June 30, 2023 | -32.21M |
| March 31, 2023 | -58.14M |
| Date | Value |
|---|---|
| December 31, 2022 | -27.09M |
| September 30, 2022 | -24.89M |
| June 30, 2022 | 174.06M |
| March 31, 2022 | -12.89M |
| December 31, 2021 | -34.20M |
| September 30, 2021 | -18.26M |
| June 30, 2021 | -16.44M |
| March 31, 2021 | 1.419M |
| December 31, 2020 | -29.11M |
| September 30, 2020 | -11.31M |
| June 30, 2020 | -13.88M |
| March 31, 2020 | -5.163M |
| December 31, 2019 | -4.731M |
| September 30, 2019 | -6.849M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Climb Bio, Inc. | -13.50M |
| MapLight Therapeutics, Inc. | -60.19M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 53.70M |
| EPS Diluted (Quarterly) | -0.8666 |
| Enterprise Value | 668.70M |
| Earnings Yield | -21.88% |
| Normalized Earnings Yield | -21.88 |